Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City with offices in NYC, London, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com.
TechBio Talks, эпизод 3: Натан Бенаич из Air Street Capital с ведущим Крисом Гибсоном
TechBio Talks, эпизод 2: Энн Карпентер из Института Брода с ведущим Крисом Гибсоном
TechBio Talks Episode 1: MIT's Regina Barzilay with Host Najat Khan
Recursion's Chris Gibson on Building a Virtual Cell to Supercharge Drug Discovery
Is AI Drug Discovery Is in Its Chip Industry Era?
New Open Source Model from MIT & Recursion Solves Major Hurdle in AI Drug Discovery
Optimizing Strategies for Clinical Development using Data and AI
Leading with Impact: Highlights from Recursion's 2025 ESG Report
Announcing the First Winner of the Chris and Summer Gibson Founder Fellowship: Elnora AI
From World Model to Virtual Cell: Recursion CEO Chris Gibson at Recursion's JPM Era of TechBio Event
Fireside Chat w/ Nobel Winner in Chemistry & CRISPR Pioneer Jennifer Doudna at Recursion's JPM Event
Recursion's "Era of TechBio" Panel at JPM Featuring Dean Li, Kimberly Powell, Alex Gorsky & Tony Kim
Najat Khan, PhD at Recursion's JPM Event: The Convergence of Biology, ML & Supercomputing Is Here
Highlights from Recursion's Era of TechBio Event with Pharma & Investment Leaders at JPM 2025
How We're Leveraging AI to Address Key Pain Points in Drug Discovery -- Najat Khan, PhD on Bloomberg
Recursion Rings Nasdaq Opening Bell, Celebrating the Era of TechBio
Recursion's 2024 Year of TechBio Breakthroughs
Live from NeurIPS: Faster, More Accurate Generation of Molecular Properties with ET-Flow
Presenting Interim Phase 1 Clinical Data for REC-617 -- a Potential Best-in-Class CDK7 Inhibitor
Yoshua Bengio: Using Machines to Make Sense of Data
Recursion Advances AI-Enabled Cancer Drug
Продвижение противоракового препарата REC-1245 на этап клинических испытаний
Najat Khan, PhD: Why I Left Pharma for TechBio
A Conversation with Yoshua Bengio: How AI Is Driving Powerful Possibilities in Scientific Discovery
Using Imaging Data for AI Drug Discovery
Inside the Recursion-Exscientia definitive agreement
Highlights from Recursion's London Office Opening
Inside the the Most Powerful Supercompuer in Pharma
How Recursion Is Collaborating with Bayer on the Next Generation of Cancer Treatments
Download Day 2024 Full Day